Molecular Diagnostics

News on lab-developed tests and emerging diagnostic technologies.

The DOJ alleged Biotheranosics promoted and performed its Breast Cancer Index test for  patients who had not been in remission for five years and who had not been taking tamoxifen.

The approval expands the firm's product range now available to European customers.

In a rapidly growing industry where 14 new genetic tests are launched daily, tracking utilization and payment is increasingly difficult, Concert Genetics' report says.

The five-year-old firm recently completed a clinical trial of the real-time PCR-based test, called ProALL-BM, on patients from a European National Registry Study.

The partnership will allow Serosep's customers to benefit from standardized diagnostic interpretation supported by artificial intelligence and automation.

Apr
26
Sponsored by
Thermo Fisher Scientific

In this webinar, the second in the “New Frontiers in Liquid Biopsy Research” series, Luca Quagliata, Senior Consultant in the Molecular Pathology Unit at University Hospital Basel, will share two specific unmet needs within his lab’s liquid biopsy research that led to the eventual evaluation, adoption, and implementation of the latest liquid biopsy Oncomine NGS solutions from Thermo Fisher.

May
01

This webinar will provide an in-depth case study demonstrating how reference standards can be used to develop and validate circulating tumor DNA (ctDNA)-based assays.

May
08

This webinar will discuss a proximity ligation-based method for studying structural variation in formalin-fixed paraffin-embedded (FFPE) tissue.

May
22
Sponsored by
Thermo Fisher Scientific

In this webinar, the third in the “New Frontiers in Liquid Biopsy Research” series, Dr. Liya Xu of the University of Southern California Michelson Center for Convergent Biosciences will discuss her team’s work using liquid biopsy technology for breast cancer research.